Company Overview

Founded in January 2013, Vigonvita Life Sciences Co., Ltd. (“Vigonvita”) is an innovation-driven biopharmaceutical company dedicated to meeting clinical needs in the treatment of neuropsychiatric, infectious and andrological diseases. Vigonvita has a complete innovative drug R&D system in Suzhou and Shanghai, undertaking all stages of the work including the drug discovery, druggability assessment, identification of candidate compounds, preclinical research, clinical research and the market launch of the innovative drug.

Vigonvita now has a competitive product pipeline. MINDVY®(VV116) was approved in Uzbekistan on December 28, 2021, for the treatment of mild, moderate, and severe COVID-19 infections in adults. 民得维®(VV116) received conditional approval for marketing from the Chinese NMPA on January 2023，and was converted from conditional to regular approval in January 2025 for the treatment of mild-to-moderate SARS-CoV-2 infection in adult patients. The Phase I clinical study of VV116 for the treatment of Respiratory Syncytial Virus (RSV) infection has been completed, and the Phase II clinical trial is currently in progress. ONVITA® (TPN171) was approved for marketing in Uzbekistan on September 20, 2022 for the treatment of erectile dysfunction (ED). The ED indication of TPN171 has completed Phase III clinical studies in China, and its new drug application (NDA) has been accepted by the NMPA; its pulmonary arterial hypertension indication is in the Phase II clinical stage in China.

The pharmaceutical manufacturing subsidiary, Vigonvita (Lianyungang) Pharmaceutical Co., Ltd is located in Lianyungang National Development Zone, China Pharmaceutical Port, covering an area of 33 acres. It has an API and formulation production system that meets domestic and international GMP standards and EHS (environmental, health, and safety) requirements. This includes a multi-functional and modular emergency production platform, which has the emergency response capability to quickly transform production technology, adjust the layout of production lines and start production in emergency situations.

Vigonvita has applied for more than 110 invention patents and now has 54 granted invention patents. We have undertaken a number of national and provincial fund projects. We have been honored as “National High-tech Enterprise”, “Suzhou Gusu Innovative Leading Talent”, “Suzhou Industrial Park Innovative Leading Talent” enterprise, “Jiangsu Province Science and Technology SME” and so on.

Vigonvita will continue to uphold the concept of innovation-driven development, and deepen its efforts in the treatment of neuropsychiatric, infectious and andrological diseases, so as to relieve patients’ pains and make contributions to the society.

Development Milestones

Research Field

  • Infectious disease

    Infectious diseases are a major threat to human life and health. In recent decades, the emergence of new re-emerging viruses and the intensification of the problem of pathogen resistance have led to a growing demand for anti-infective drugs in clinical practice, especially for infectious diseases that lack targeted therapeutic drug, and the need for innovative drug is extremely urgent.
    查看更多 +

  • Neuropsychiatric disease

    Neuropsychiatric diseases are a group of disorders that affect the nervous system and mental health, including, but not limited to, Alzheimer's disease, Parkinson's disease, epilepsy, schizophrenia, depression and anxiety. These disorders may result in emotional, behavioral, cognitive and social abnormalities that affect an individual's daily life and function. The incidence of neuropsychiatric diseases is increasing year by year with the development of society and the improvement of living standards, and the accelerated aging of the population.
    查看更多 +
    神经精神系统疾病

  • Andrology diseases

    Andrological disorders encompass a range of conditions impacting the male urinary and reproductive systems. These include, but are not limited to, erectile dysfunction, premature ejaculation, prostatitis, and prostate hyperplasia. Factors such as high levels of stress, irregular lifestyle patterns, unhealthy dietary habits, and insufficient physical activity have contributed to an increasing prevalence of these disorders among younger age groups in China.
    查看更多 +

Company Presence

Headquarters of in Suzhou, with R&D centers set up in Suzhou and Shanghai. Established an API and formulation manufacturing plant in Lianyungang, Jiangsu Province, to build a pharmaceutical manufacturing system that meets GMP standards and EHS (environment, health and safety) requirements. This includes a multi-functional and modular emergency production platform, which has the emergency response capability to quickly transform production technology, adjust the layout of production lines and start production in emergency situations. Vigonvita Tashkant was established in Uzbekistan, tasked with the registration and sales of the products in Uzbekistan. Currently, three products have been approved for marketing in Uzbekistan. Based on this, Vigonvita is further expanding its business in other countries such as North Africa, Central Asia, the Middle East, and Russia.

Uzbekistan
乌兹别克斯坦
Lianyungang
连云港
Suzhou
苏州
Shanghai
上海
map

Management Team

Honors & Qualifications

    Company News

    More News +